Joong Hoon Park Associate Professor

Applied Animal Science

Reproductive physiology


Research Paper


Research Project


Technology Transfer


  • B.S., Dept. of Animal Science and Biotechnology, Seoul National University, 1998
  • M.S., Dept. of Animal Science and Biotechnology, Seoul National University, 2000
  • Ph.D., Dept. of Animal Science, Center for Regenerative Biology, University of Connecticut, 2009

Professional Experiences

  • Project leader, Institute of Drug Discovery, LG Life Sciences R&D Park, 2013.01-2016.08
  •     - Novel GPCR antagonist for anti-diabetes and anti-obesity
         - Cancer genomics in Korean patients with colon cancer
        - Knowledge-based approach on metabolic disorders
         - Computational drug repositioning
  • Study Director, Drug Development Center, LG Life Sciences R&D Park, 2000.02-2012.12
  •     - Phase 1 IND approval of LC28-0126 for myocardial infarction, MFDS, Korea
        - NDA approval of Zemiglo for type 2 diabetes, MFDS, Korea
        - NDA approval of Factive for upper respiratory tract infection, ISP, Chile
        - GLP certificate of developmental and reproductive toxicology studies, KFDA, Korea

Society Memberships

  • The Korea Society of Nonclinical Study (한국비임상시험연구회)
  •     - Advisory board (2016-present)
        - General affair (2014-2015)

Research Interests

  • Nonclinical development of biopharmaceuticals
  • Epigenomic dynamics in stem cell differentiation
  • Knowledge-based target identification and validation of disease and economic traits
  • Gut microbiota in metabolic disorders


  • Topics in regulatory toxicology (규제독성학특강)
  • Topics in nonclinical studies (비임상연구특강)


  • Best Project Award, LG Life Sciences, 2014
  • Outstanding Graduate Student Award, Dept. of Animal Science, University of Connecticut, 2009
  • Larry Ewing Memorial Trainee Travel Fund Scholarship, Society for the Study of Reproduction, 2009
  • Graduate Research Award, College of Agriculture and Natural Resources Graduate Council Research Forum, University of Connecticut, 2007

Publications (selected)

  • Choi KH, Park JK, Son D, Hwang JY, Lee DK, Ka H, Park J, Lee CK. Reactivation of endogenous genes and epigenetic remodeling are barriers for generating transgene-free induced pluripotent stem cells in pig. PLoS ONE. 2016 Jun 23;11(6):e0158046
  • Park J, Maria FS, Oh HM, Park J, Kang J, Tian XC. Gene-specific assessment of guanine oxidation as an epigenetic modulator for cardiac specification of mouse embryonic stem cells. PLoS ONE. 2016 Jun 1;11(6):e0155792
  • Park DY, Choi C, Shin E, Lee JH, Kwon CH, Jo HJ, Kim HR, Kim HS, Oh N, Lee JS, Park OK, Park E, Park J, Shin JY, Kim JI, Seo JS, Park HD, Park J. NTRK1 fusions for the therapeutic intervention of Korean patients with colon cancer. Oncotarget. 2016 Feb 16;7(7):8399-412
  • Shin EJ, KIM SR, Lee OC, Kim SH, Park J. Drug signature-based finding of possible clinical use LC28-0126 for neutrophilic bronchial asthma. Sci Reports. 2015 Dec 2;5:17784
  • Park J, Lai L, Samuel MS, Wax D, Prather RS, Tian XC. Disruption of mitochondrion-to-nucleus interaction in deceased cloned piglets. PLoS ONE. 2015 Jun 11;10(6):e0129378
  • Tang Y, Luo Y, Jiang Z, Ma Y, Lin C-J, Kim C, Carter M, Amano T, Park J, Kish S, Tian X. Jak/Stat3 signaling promotes somatic cell reprogramming by epigenetic regulation. Stem Cells. 2012 Dec;30(12):2645-56
  • Park J, Park E, Ahn BH, Kim HJ, Park JH, Koo SY, Kwak HS, Song M, Yim HJ, Seo DO, Kim SH. NecroX-7 prevents oxidative stress-induced cardiomyopathy by inhibition of NADPH oxidase activity in rats. Toxicol Appl Pharmacol. 2012 Aug 15;263(1):1-6